MTOR and endometrial cancer: A specific endometrial cancer organoid line was most sensitive to everolimus (an inhibitor of mammalian target of rapamycin mTOR), which suggested a strong dependence on the PI3K-AKT pathway and was in line with mutations in the pathway’s signaling mediators (PTEN, PIK3CA, AKT1) (Borretto et al., 2019).